Promoting Prevention and Targeting Remission of Asthma
Asthma is a common, multifaceted respiratory disease with a major impact on quality of life. Despite increased insights into mechanisms underlying various asthma phenotypes and endotypes and the availability of targeted biologic treatment options, the disease remains uncontrolled in a substantial proportion of patients with risk of exacerbations, requiring systemic corticosteroids, and with progressive disease. Current international guidelines advocate for a personalized management approach to patients with uncontrolled severe asthma. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) asthma expert panel was convened to discuss strategies to optimize asthma care and to prevent systemic corticosteroid overuse and disease progression. In this meeting report, we summarize current concepts and recommendations and provide a rationale to implement personalized asthma management at earlier stages of the disease. The ultimate goal is to move away from the current one-size-fits-most concept, which focuses on a symptom-driven treatment strategy, and shift toward a phenotype- and endotype-targeted approach aimed at curbing the disease course by improving clinical outcomes and preserving health-related quality of life. Herein, we provide a consensus view on asthma care that advocates a holistic approach and highlight some unmet needs to be addressed in future clinical trials and population studies.
Authors
- Liam Gabriel Heaney (ORCID: https://orcid.org/0000-0002-9176-5564)
- Elizabeth Van Staeyen
- Miloš Jeseňák (ORCID: https://orcid.org/0000-0001-7976-2523)
- Anna Bobčáková (ORCID: https://orcid.org/0000-0002-2794-9529)
- Nicola A. Hanania (ORCID: https://orcid.org/0000-0003-3087-9530)
- Wytske J. Fokkens (ORCID: https://orcid.org/0000-0003-4852-229X)
- Santiago Quirce (ORCID: https://orcid.org/0000-0001-8086-0921)
- Peter W. Hellings (ORCID: https://orcid.org/0000-0001-6898-688X)
- Dermot Ryan (ORCID: https://orcid.org/0000-0002-4115-7376)
- Zuzana Diamant (ORCID: https://orcid.org/0000-0003-0133-0100)
- Ratko Djukanović (ORCID: https://orcid.org/0000-0001-6039-5612)
- Leif Hilding Bjermer (ORCID: https://orcid.org/0000-0002-3441-8099)
- Diego M. Conti (ORCID: https://orcid.org/0000-0002-8896-495X)
- Ian Pavord (ORCID: https://orcid.org/0000-0002-4288-5973)
- Glenis Scadding
- Mina Gaga
Institutions
- Queen's University Belfast (GB)
- University Medical Center Groningen (NL)
- Baylor College of Medicine (US)
- Lund University (SE)
- Royal London Hospital (GB)
- Royal National Orthopaedic Hospital (GB)
- Forum of European National Highway Research Laboratories (BE)
- University of Oxford (GB)
- Hospital La Paz Institute for Health Research (ES)
- NIHR Southampton Biomedical Research Centre (GB)
- Hygeia Hospital (GR)
- Skåne University Hospital (SE)
- Oxford BioMedica (United Kingdom) (GB)
- Amsterdam University Medical Centers (NL)
- Martin University Hospital (SK)
- University of Southampton (GB)
- University College London (GB)
- Universidad Autónoma de Madrid (ES)
- Comenius University Bratislava (SK)
- University of Edinburgh (GB)
- KU Leuven (BE)
Publication Details
- Journal
- CHEST Journal
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1016/j.chest.2024.11.035
- Citations
- 13
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.25
Funders
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Teva Pharmaceutical Industries
- CSL Behring
- Regeneron Pharmaceuticals
- Mylan
- Allergy Therapeutics
- Genentech
- Novartis Pharmaceuticals UK Limited
- Sanofi Genzyme
- Medical Research Council